Innovation in pharma today means faster ‘time to insight’. However, trying to innovate with disconnected, fragmented data is slow, costly and frustrating—for both pharma companies and patients. In this paper, industry leaders weigh in on what’s preventing pharma companies from escaping data silos and a new way forward.
Embracing FAIR data principles, the MarkLogic Pharma Research Hub enables organisations to securely integrate their data from disparate silos. External sources of data can be brought in to enrich internal data sets. On top of this, advanced search and semantics make research data findable in one place, near instantaneously. A single point of truth enables […]
For pharmaceutical companies, bringing a new drug to market can now require up to $2.6 billion and 15 years — slowing potentially life-saving drugs from getting to the patients who need them and resulting in abandonment of drug trials when faced with potential failure.
MarkLogic helps pharmaceutical organizations resolve the critical data challenges that traditionally slow R&D processes and the development of new drugs — making it easier to share information, reduce the burden on IT, and better leverage machine learning and AI.
Integrate all pharma data 10x faster with the Data Hub Service for Pharma R&D—the hub is a single pane of glass that provides easy access to the widest possible array of R&D data available, including publications, authors, genes, drugs, and more.
MarkLogic gives pharmaceutical companies the ability to streamline operations and accelerate time to market for new pharmaceutical products. Learn how the operational data hub facilitates a more accurate, transparent view of data—from R&D to the supply chain—eliminating fragmentation while enabling new business models and increased operational efficiency.
Join this webinar to learn how a next-generation semantic operational data hub can be used to build dynamic cohorts in real-time using all forms of real world data—significantly shortening the time traditionally wasted on data wrangling and ETL—to achieve faster results at a lower cost.
MarkLogic’s operational data hub enhances detection of adverse events at every point in the drug lifecycle—from clinical trial through post-market—empowering pharmaceutical companies to avoid regulatory roadblocks and costly fines while protecting their reputation with both patients and regulators.
Join this webinar, presented by Xtalks, as data experts explore the growing challenges and unrealized potential of using real world data for pharmacovigilance. As the volume of data continues to grow, harmonizing, semantic enrichment, and making searchable all of the available data is the first step to detecting relevant signals and exposing critical insights.
Amgen’s Dr. Clare Augustine, Taxonomy Management Lead, joins MarkLogic Healthcare, Life Sciences, and Manufacturing leaders to discuss how industry-leading companies like Amgen and Chevron have achieved a 360 view of their data—connecting data from across the supply chain to improve lane carrier operations and compliance—at less cost.
In this ISPOR Educational webinar, industry experts discuss how data science and digital data technologies are empowering organizations to overcome data obstacles while transforming the way real world evidence is generated and used.
Designed specifically to set your company on an accelerated track to real world evidence delivery, our Quick Start Service features the secure MarkLogic database as an agile, scalable data platform that solves critical limitations and inefficiencies in multi-structured data integration, data governance, and search and discovery.
MarkLogic World 2018: Across the healthcare and life sciences industries, there is a lot of talk about innovation. But, what is actually being done that is making a measurable difference? Check out this panel discussion.
Watch this on-demand webinar with RWE & HEOR expert, Anita Burrell and MarkLogic Chief Stratgist, Bill Fox, to learn how a data-centric approach enables organizations to rapidly and securely integrate real world data, reducing the time required to develop real world evidence.